AQR Capital Management
VRDN icon

AQR Capital Management’s Viridian Therapeutics VRDN Stock Holding History

AQR Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Buy
127,301
+107,093
+530% +$1.73M ﹤0.01% 2527
2026
Q1 		$395K Buy
+20,208
New +$600K ﹤0.01% 3258
2023
Q3 		– Sell
-12,005
Closed -$286K – 2392
2023
Q2 		$286K Buy
12,005
+1,634
+16% +$41.9K ﹤0.01% 1959
2023
Q1 		$264K Buy
10,371
+2,968
+40% +$95.2K ﹤0.01% 1977
2022
Q4 		$216K Buy
+7,403
New +$171K ﹤0.01% 2062

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

AQR Capital Management's VRDN Position: Q2 2026 in Review

AQR Capital Management increased its Viridian Therapeutics (VRDN) stake by 530% in Q2 2026, buying an estimated $1.73M and bringing the position to 127,301 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2527.

AQR Capital Management first reported a position in VRDN in Q4 2022 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • AQR Capital Management held 127,301 shares of Viridian Therapeutics worth $2.34M as of Q2 2026.
  • AQR Capital Management bought 107,093 Viridian Therapeutics shares in Q2 2026, an estimated $1.73M.
  • Viridian Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2527 holding.
  • AQR Capital Management first reported a position in Viridian Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.